Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity

Core Insights - Zealand Pharma announced positive topline results from the Phase 2 ZUPREME-1 trial for petrelintide, showing significant weight reduction in individuals with overweight and obesity [2][3][6] Group 1: Trial Results - The trial involved 493 participants with a mean baseline BMI of 37 kg/m, achieving a mean body weight reduction of up to 10.7% from baseline after 42 weeks, compared to 1.7% with placebo (p-value <0.001) [2][3][7] - 98% of participants in the treatment arm successfully escalated to the targeted maintenance dose, indicating strong adherence and tolerability [3][4] - The treatment demonstrated a favorable tolerability profile, with a treatment discontinuation rate of 4.8% for petrelintide versus 4.9% for placebo [4][5] Group 2: Safety and Adverse Events - No unexpected safety signals were observed, with gastrointestinal-related adverse events being mild and comparable to placebo [5][6] - The proportion of participants experiencing vomiting was lower in the petrelintide group, with no cases in the maximally effective dose arm [4][5] - Withdrawal rates due to any reason were 8.4% for petrelintide compared to 13.6% for placebo, indicating better retention in the treatment group [5] Group 3: Future Developments - Zealand Pharma plans to advance the program towards Phase 3 initiation later in 2026, with additional trials for petrelintide monotherapy and combination therapies expected [6][8] - A collaboration with Roche for co-development and commercialization of petrelintide was established in 2025, enhancing the potential market reach [9] Group 4: About Petrelintide - Petrelintide is a long-acting amylin analog designed for once-weekly subcutaneous administration, showing potential for weight loss comparable to GLP-1 receptor agonists but with improved tolerability [13]